Business
Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections
Study to evaluate the efficacy and safety of fosmanogepix in adults with invasive mold infectionsStudy completion expected in Q1 2028 Allschwil, Switzerland, July 29, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today the initiation of FORWARD-IM, a phase 3 registrational study evaluating the efficacy and safety of its broad-spectrum antifungal
About this update from Basilea Pharmaceutica Ag
[{"type":"image","alt":"Basilea Pharmaceutica AG, Allschwil","displaySize":"","headline":null,"caption":"Basilea Pharmaceutica AG, Allschwil","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/a45f97ddaed549237a3a9f58773435b7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/863aV4U6H3aPDpGW_iaFpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a45f97ddaed549237a3a9f58773435b7","width":300,"height":102}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Study to evaluate the efficacy and safety of fosmanogepix in adults with invasive mold infections","length":97,"tagName":"p"}]},{"val":[{"type":"text","content":"Study completion expected in Q1 2028","length":36,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":133,"olType":false},{"type":"text","content":"Allschwil, Switzerland, July 29, 2025","length":37,"tagName":"p"},{"type":"text","content":"Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today the initiation of FORWARD-IM, a phase 3 registrational study evaluating the efficacy and safety of its broad-spectrum antifungal fosmanogepix for the treatment of adult patients with invasive mold infections.[1]","length":410,"tagName":"p"},{"type":"text","content":"Fosmanogepix is a first-in-class antifungal with a novel mechanism of action and is available in both intravenous and oral formulations. It has been evaluated for efficacy and safety in a phase 1 and phase 2 program, including three open-label phase 2 studies for the treatment of Candidemia, including Candida auris, and invasive mold infections.[2, 3, 4, 5, 6]","length":362,"tagName":"p"},{"type":"text","content":"The FORWARD-IM study is the second phase 3 study for fosmanogepix, following the initiation of FAST-IC in September 2024, a randomized, double-blind phase 3 registrational study in adult patients with candidemia and/or invasive candidiasis.[7]","length":243,"tagName":"p"},{"type":"text","content":"Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: "Our phase 3 program with fosmanogepix allows us to fully explore the clinical benefit of this important new treatm...